Overview

Korsana Biosciences develops therapeutics for neurodegenerative diseases, with KRSA-028 as its lead candidate for Alzheimer's disease. KRSA-028 is a next-generation shuttled monoclonal antibody that targets amyloid beta, using Korsana’s THETA platform to cross the blood-brain barrier via a TfR1 shuttle and Fc engineering to deliver higher drug levels in the brain. The THETA shuttle is designed to improve brain delivery and tolerability, enabling subcutaneous administration instead of intravenous infusions. The goal is to advance THETA-enabled therapies through clinical trials, with planned safety data in healthy volunteers in mid-2027 and initial proof-of-concept data for amyloid plaque clearance by the end of 2027, supported by funding through 2028.

Significant Headcount Growth